What Biotech Can Learn from Insurance: Actuarial Thinking in Drug Development
Biotech and insurance rarely appear in the same sentence unless one is covering the other. One traffics in breakthroughs and billion-dollar valuations. The other concerns itself with probabilities, premiums, and the statistically inevitable demise of us all. Yet, it might be time for biotech to stop aspiring to become the